Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net income including noncontrolling interests in subsidiaries	$ 150,365	$ 109,231
Adjustments to reconcile net income including noncontrolling interests in subsidiaries to net cash provided by (used in) operating activities:
Change in fair value of investment, net	2,752	(5,474)
Gain on sale of investment	(3,591)	(8,187)
Depreciation and amortization	10,688	4,800
Amortization of debt discount and issuance costs	110	7,051
Change in fair value of Series A redeemable convertible preferred stock embedded derivatives	(8,280)	8,754
Change in fair value of Series A warrants	4,651	3,072
Change in fair value of Series B warrants	44,037	46,412
Compensation expense for share-based awards	2,053	1,662
Loss on foreign currency exchange	89	4,905
Change in fair value of equity securities	(87,527)	(176,173)
Gain on sale of equity securities	(116,129)	(7,352)
Gain on sale of prepaid investment and derivative	0	(2,845)
Earnings on equity investment in joint venture	(3,530)	0
Changes in assets and liabilities:
Accounts receivable	(747)	5
Inventories	1,906	0
Prepaid expenses and other assets	(78)	(2,919)
Accounts payable and accrued expenses	760	(2,546)
Royalties and contingent legal fees payable	301	(16)
Deferred revenue	(246)	0
Deferred income tax liabilities	15,742	0
Net cash provided by (used in) operating activities	13,326	(19,620)
Cash flows from investing activities:
Acquisition, net of cash acquired	(33,250)	0
Patent acquisition	(21,000)	(13,780)
Sale of investment at fair value	3,591	12,409
Purchases of equity securities	(66,624)	(46,492)
Sales of equity securities	154,784	228,873
Maturities and sales of debt securities	0	118,459
Cash distributed for notes receivable	(4,021)	0
Acquisition of Life Sciences Portfolio equity securities	0	(280,263)
Distributions received from equity investment in joint venture	2,362	0
Distributions to noncontrolling interests in operating subsidiary	0	(409)
Purchases of property and equipment	(91)	(199)
Net cash provided by investing activities	35,751	18,598
Cash flows from financing activities:
Repurchase of common stock	(4,012)	(3,998)
Issuance of Senior Secured Notes, net of lender fee	115,000	110,437
Paydown of Senior Secured Notes	(50,000)	0
Senior Secured Notes issuance costs paid to other parties	0	(496)
Dividend on Series A Redeemable Convertible Preferred Stock	(1,452)	(1,382)
Issuance of Series B warrants	0	4,600
Proceeds from exercise of stock options	202	48
Net cash provided by financing activities	59,738	109,209
Increase in cash and cash equivalents and restricted cash	108,815	108,187
Cash and cash equivalents and restricted cash, beginning	200,546	92,359
Cash and cash equivalents and restricted cash, ending	309,361	200,546
Supplemental schedule of cash flow information:
Interest paid	7,336	1,259
Income taxes paid (refunded)	25	(3,482)
Patent acquisition in exchange of notes receivable	4,000	0
Patent acquisition accrued liabilities	5,000	0
Distribution to noncontrolling interests in subsidiaries	$ 1,168	$ 0